Aktis Oncology, Inc. in brief
Aktis Oncology, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It employs about 79 people. Its shares trade under the symbol AKTS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Aktis Oncology, Inc.
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type, yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting.
From the company's annual report filed with the US SEC: read the report
Aktis Oncology, Inc. timeline
- 2024
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- 🔔Initial public offeringFinal prospectus filed with the SEC on 9 January 2026; shares registered for exchange trading on 7 January 2026.
Events of Aktis Oncology, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Quarterly results
Latest quarter to Sep 2026: revenue $4M (+146.8% on a year earlier), net income $-30M.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- May 11, 20268-KCurrent reportResults of operations
- May 11, 202610-QQuarterly report · period to Mar 2026
- Apr 16, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Mar 30, 202610-KAnnual report · period to Dec 2025
- Mar 30, 20268-KCurrent reportResults of operations
- Jan 12, 20268-KCurrent reportBylaws amended
- Jan 9, 2026424B4IPO prospectus
- Jan 7, 2026S-1/AIPO registration (amended)
Official filings of Aktis Oncology, Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $265 M
- Total liabilities
- $78 M
- Total equity
- $-146 M
As of December-2025
Top 100 institutional investors in Aktis Oncology, Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | MPM Bioimpact LLC | 4,835,872 | 0 (0.00%) | $94 M | Nov 16, 2026 |
| 2 | EcoR1 Capital, LLC | 4,824,469 | 0 (0.00%) | $94 M | Nov 16, 2026 |
| 3 | Blue Owl Capital Holdings LP | 3,343,827 | +273,608 (+8.91%) | $65 M | Nov 13, 2026 |
| 4 | T. Rowe Price Investment Management, Inc. | 3,333,026 | +1,281,579 (+62.47%) | $65 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 2,780,745 | +502,387 (+22.05%) | $54 M | Nov 13, 2026 |
| 6 | RTW Investments, LP | 1,592,043 | 0 (0.00%) | $31 M | Nov 16, 2026 |
| 7 | Wellington Management Group LLP | 1,471,969 | -494,275 (-25.14%) | $29 M | Nov 16, 2026 |
| 8 | Price T Rowe Associates Inc /MD/ | 1,184,617 | +421,118 (+55.16%) | $23 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 1,180,925 | +363,850 (+44.53%) | $23 M | Nov 13, 2026 |
| 10 | Eventide Asset Management, LLC | 1,065,000 | +558,000 (+110.06%) | $21 M | Nov 13, 2026 |
| 11 | State Street Corp | 1,050,480 | +566,470 (+117.04%) | $20 M | Nov 12, 2026 |
| 12 | Baker Bros. Advisors LP | 996,351 | 0 (0.00%) | $19 M | Nov 16, 2026 |
| 13 | Merck & Co., Inc. | 952,844 | 0 (0.00%) | $19 M | Nov 13, 2026 |
| 14 | ArrowMark Colorado Holdings LLC | 852,159 | +606,287 (+246.59%) | $17 M | Nov 16, 2026 |
| 15 | Octagon Capital Advisors LP | 713,000 | -247,847 (-25.79%) | $14 M | Nov 16, 2026 |
| 16 | Geode Capital Management, LLC | 690,427 | +169,690 (+32.59%) | $13 M | Nov 6, 2026 |
| 17 | Avidity Partners Management LP | 484,200 | 0 (0.00%) | $9 M | Nov 16, 2026 |
| 18 | Two Sigma Investments, LP | 436,467 | +405,553 (+1311.87%) | $8 M | Nov 16, 2026 |
| 19 | a16z Capital Management, L.L.C. | 415,000 | 0 (0.00%) | $8 M | Nov 16, 2026 |
| 20 | Affinity Asset Advisors, LLC | 350,000 | New | $7 M | Nov 13, 2026 |
| 21 | Alyeska Investment Group, L.P. | 290,000 | 0 (0.00%) | $6 M | Nov 16, 2026 |
| 22 | Northern Trust Corp | 236,638 | +56,063 (+31.05%) | $5 M | Nov 16, 2026 |
| 23 | Charles Schwab Investment Management Inc | 230,818 | +63,976 (+38.35%) | $4 M | Nov 16, 2026 |
| 24 | TD Asset Management Inc | 203,494 | +97,592 (+92.15%) | $4 M | Nov 13, 2026 |
| 25 | Vanguard Portfolio Management LLC | 198,386 | +53,166 (+36.61%) | $4 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 26 | Millennium Management LLC | 192,728 | New | $4 M | Nov 16, 2026 |
| 27 | Vanguard Fiduciary Trust Co | 183,780 | +49,946 (+37.32%) | $4 M | Nov 13, 2026 |
| 28 | Woodline Partners LP | 172,608 | +72,608 (+72.61%) | $3 M | Nov 16, 2026 |
| 29 | Mirador Capital Partners LP | 133,558 | +93,434 (+232.86%) | $3 M | Oct 9, 2026 |
| 30 | TCG Crossover Management, LLC | 133,457 | -563,103 (-80.84%) | $3 M | Nov 16, 2026 |
| 31 | Point72 Asset Management, L.P. | 132,886 | New | $3 M | Nov 16, 2026 |
| 32 | Citadel Advisors LLC | 115,857 | +90,320 (+353.68%) | $2 M | Nov 16, 2026 |
| 33 | Jump Financial, LLC | 112,187 | +79,408 (+242.25%) | $2 M | Nov 13, 2026 |
| 34 | UBS Group AG | 110,322 | +10,362 (+10.37%) | $2 M | Nov 10, 2026 |
| 35 | Quantinno Capital Management LP | 109,075 | +62,188 (+132.63%) | $2 M | Nov 13, 2026 |
| 36 | Bank Of America Corp /de/ | 106,894 | +34,059 (+46.76%) | $2 M | Nov 16, 2026 |
| 37 | Morgan Stanley | 91,569 | +28,933 (+46.19%) | $2 M | Nov 13, 2026 |
| 38 | Goldman Sachs Group Inc | 85,135 | +63,857 (+300.11%) | $2 M | Nov 16, 2026 |
| 39 | Manufacturers Life Insurance Company, The | 80,065 | +32,021 (+66.65%) | $2 M | Nov 13, 2026 |
| 40 | Polen Capital Management LLC | 72,795 | +9,281 (+14.61%) | $1 M | Nov 13, 2026 |
| 41 | BNP Paribas Financial Markets | 70,816 | +67,536 (+2059.02%) | $1 M | Nov 12, 2026 |
| 42 | Marshall Wace, LLP | 69,158 | New | $1 M | Nov 13, 2026 |
| 43 | Bank of New York Mellon Corp | 67,042 | +17,792 (+36.13%) | $1 M | Nov 5, 2026 |
| 44 | Barclays PLC | 66,716 | -84,980 (-56.02%) | $1 M | Nov 6, 2026 |
| 45 | Tidal Investments LLC | 65,989 | +8,930 (+15.65%) | $1 M | Nov 13, 2026 |
| 46 | Quadrature Capital Ltd | 61,695 | New | $1 M | Nov 13, 2026 |
| 47 | Nuveen, LLC | 60,357 | +10,541 (+21.16%) | $1 M | Nov 10, 2026 |
| 48 | HRT Financial LP | 57,873 | New | $1 M | Nov 13, 2026 |
| 49 | Trexquant Investment LP | 54,037 | New | $1 M | Nov 16, 2026 |
| 50 | XTX Topco Ltd | 51,513 | New | $1 M | Nov 16, 2026 |
| 51 | AQR Capital Management LLC | 37,478 | -10,645 (-22.12%) | $1 M | Nov 16, 2026 |
| 52 | Ameriprise Financial Inc | 36,059 | +16,059 (+80.30%) | $1 M | Nov 16, 2026 |
| 53 | Sofinnova Investments, Inc. | 31,605 | -831 (-2.56%) | $1 M | Nov 16, 2026 |
| 54 | Rhumbline Advisers | 31,196 | +4,251 (+15.78%) | $1 M | Nov 10, 2026 |
| 55 | Renaissance Technologies LLC | 30,539 | -64,861 (-67.99%) | $1 M | Nov 12, 2026 |
| 56 | Raymond James Financial Inc | 30,449 | -20,015 (-39.66%) | $1 M | Nov 12, 2026 |
| 57 | Weiss Asset Management LP | 30,422 | New | $1 M | Nov 16, 2026 |
| 58 | Ghisallo Capital Management LLC | 25,000 | 0 (0.00%) | $0 M | Nov 16, 2026 |
| 59 | Seven Grand Managers, LLC | 25,000 | 0 (0.00%) | $0 M | Nov 16, 2026 |
| 60 | Tudor Investment Corp Et Al | 24,980 | +3,578 (+16.72%) | $0 M | Nov 16, 2026 |
| 61 | Deutsche Bank AG\ | 24,350 | +3,328 (+15.83%) | $0 M | Nov 6, 2026 |
| 62 | Algert Global LLC | 22,820 | New | $0 M | Nov 17, 2026 |
| 63 | Rafferty Asset Management, LLC | 22,132 | New | $0 M | Nov 13, 2026 |
| 64 | Alliancebernstein L.P. | 17,900 | New | $0 M | Nov 16, 2026 |
| 65 | MetLife Investment Management, LLC | 16,542 | +3,548 (+27.30%) | $0 M | Nov 16, 2026 |
| 66 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 15,393 | +5,624 (+57.57%) | $0 M | Nov 16, 2026 |
| 67 | NLB Skladi, upravljanje premozenja, d.o.o. | 15,000 | New | $0 M | Oct 22, 2026 |
| 68 | Gsa Capital Partners LLP | 14,946 | New | $0 M | Nov 16, 2026 |
| 69 | Virtus Investment Advisers, LLC | 14,470 | -450 (-3.02%) | $0 M | Nov 12, 2026 |
| 70 | Jpmorgan Chase & Co | 14,129 | +5,294 (+59.92%) | $0 M | Nov 12, 2026 |
| 71 | Invesco Ltd. | 14,115 | -793 (-5.32%) | $0 M | Nov 12, 2026 |
| 72 | American Century Companies Inc | 13,895 | New | $0 M | Nov 12, 2026 |
| 73 | State Of Wisconsin Investment Board | 11,974 | New | $0 M | Nov 16, 2026 |
| 74 | Wells Fargo & Company/mn | 11,261 | -16,398 (-59.29%) | $0 M | Nov 16, 2026 |
| 75 | Vanguard Global Advisers, LLC | 10,192 | +3,306 (+48.01%) | $0 M | Nov 13, 2026 |
| 76 | Mercer Global Advisors Inc /adv | 10,115 | New | $0 M | Nov 16, 2026 |
| 77 | Caprock Group, LLC | 10,000 | +92 (+0.93%) | $0 M | Nov 17, 2026 |
| 78 | Citigroup Inc | 9,756 | -3,421 (-25.96%) | $0 M | Nov 4, 2026 |
| 79 | Russell Investments Group, Ltd. | 8,391 | +637 (+8.22%) | $0 M | Nov 6, 2026 |
| 80 | Police & Firemen's Retirement System of New Jersey | 7,551 | +2,021 (+36.55%) | $0 M | Nov 9, 2026 |
| 81 | New York State Common Retirement Fund | 7,500 | 0 (0.00%) | $0 M | Nov 17, 2026 |
| 82 | Lanark Financial, Inc. | 5,567 | +209 (+3.90%) | $0 M | Oct 26, 2026 |
| 83 | Aquatic Capital Management LLC | 3,977 | New | $0 M | Nov 16, 2026 |
| 84 | FMR LLC | 3,398 | -282,233 (-98.81%) | $0 M | Nov 10, 2026 |
| 85 | Legal & General Group Plc | 2,689 | +627 (+30.41%) | $0 M | Nov 16, 2026 |
| 86 | Ameritas Investment Partners, Inc. | 2,550 | +625 (+32.47%) | $0 M | Nov 13, 2026 |
| 87 | Strs Ohio | 2,200 | -900 (-29.03%) | $0 M | Oct 30, 2026 |
| 88 | Osaic Holdings, Inc. | 1,673 | New | $0 M | Nov 12, 2026 |
| 89 | Royal Bank Of Canada | 1,610 | +813 (+102.01%) | $0 M | Nov 16, 2026 |
| 90 | Jones Financial Companies Lllp | 1,600 | New | $0 M | Nov 13, 2026 |
| 91 | Global Retirement Partners, LLC | 1,537 | +1,142 (+289.11%) | $0 M | Nov 10, 2026 |
| 92 | Silver Grove Financial Group, Inc. | 1,449 | New | $0 M | Nov 5, 2026 |
| 93 | Rockefeller Capital Management L.P. | 1,422 | +1,025 (+258.19%) | $0 M | Nov 13, 2026 |
| 94 | GK Wealth Management LLC | 1,350 | New | $0 M | Oct 9, 2026 |
| 95 | Tower Research Capital LLC (TRC) | 1,312 | -956 (-42.15%) | $0 M | Nov 16, 2026 |
| 96 | Sterling Capital Management LLC | 823 | +639 (+347.28%) | $0 M | Oct 22, 2026 |
| 97 | Aster Capital Management (DIFC) Ltd | 748 | New | $0 M | Nov 12, 2026 |
| 98 | State of Wyoming | 653 | -332 (-33.71%) | $0 M | Oct 28, 2026 |
| 99 | Arax Advisory Partners | 452 | +67 (+17.40%) | $0 M | Nov 12, 2026 |
| 100 | Quarry LP | 445 | +411 (+1208.82%) | $0 M | Nov 16, 2026 |
Superinvestors holding Aktis Oncology, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Polen Capital · Polen Capital's team$1 M+9,281 · Sep 30, 2026
Mutual funds holding Aktis Oncology, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Health Care FundWellington Management Company LLP | 1.46 M | $32 M | — | 0.08% | −28% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc. | 676,577 | $22 M | — | 0.23% | +10% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 585,135 | $19 M | — | <0.01% | −3.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 545,302 | $18 M | — | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 507,000 | $16 M | — | 0.91% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc. | 358,947 | $12 M | — | 0.23% | +12% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 333,745 | $11 M | — | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 209,816 | $7 M | — | <0.01% | +0.1% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 196,735 | $6 M | — | 0.04% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 283,355 | $6 M | — | 0.11% | −26% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 266,503 | $6 M | — | 0.09% | no change | May 29, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 163,403 | $5 M | — | 0.05% | −20% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 232,435 | $5 M | — | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 133,328 | $4 M | — | 0.03% | +56% | Jun 30, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 105,570 | $3 M | — | 1.2% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 105,593 | $2 M | — | 0.01% | +2571% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 97,084 | $2 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 59,825 | $2 M | — | 0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 58,563 | $2 M | — | 0.18% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 88,457 | $2 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 39,040 | $1 M | — | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 51,557 | $1 M | — | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 41,318 | $1 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 23,229 | $1 M | — | 0.13% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 22,979 | $1 M | — | 0.02% | +13% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 20,013 | $1 M | — | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 28,152 | $1 M | — | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 28,570 | $1 M | — | <0.01% | +94% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 28,478 | $1 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 16,038 | $1 M | — | 0.14% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc. | 22,032 | $0 M | — | 0.01% | +17% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 13,687 | $0 M | — | 0.03% | +66% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 13,600 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 10,724 | $0 M | — | 0.02% | +5.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,238 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 9,357 | $0 M | — | <0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 13,567 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 9,241 | $0 M | — | 0.01% | −22% | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 13,916 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 13,000 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 8,029 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 7,100 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 10,145 | $0 M | — | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 6,809 | $0 M | — | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 6,754 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 10,088 | $0 M | — | 0.01% | +2520% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 6,221 | $0 M | — | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,660 | $0 M | — | <0.01% | +125% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 8,504 | $0 M | — | 0.01% | new | May 31, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc. | 8,264 | $0 M | — | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 5,193 | $0 M | — | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 7,607 | $0 M | — | 0.01% | +5986% | May 31, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 4,864 | $0 M | — | 0.09% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,668 | $0 M | — | 0.01% | −30% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,597 | $0 M | — | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 4,392 | $0 M | — | 0.02% | +15% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,229 | $0 M | — | <0.01% | +1.8% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,333 | $0 M | — | 0.02% | +16% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc. | 5,175 | $0 M | — | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 3,288 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,236 | $0 M | — | 0.02% | +39% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 3,140 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,500 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,887 | $0 M | — | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,598 | $0 M | — | 0.02% | +38% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,667 | $0 M | — | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 3,540 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,148 | $0 M | — | 0.01% | +53% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,974 | $0 M | — | <0.01% | +1.8% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,925 | $0 M | — | 0.02% | +14% | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 2,403 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,275 | $0 M | — | 0.01% | +1.6% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,551 | $0 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,473 | $0 M | — | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,903 | $0 M | — | 0.02% | +19% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,285 | $0 M | — | 0.03% | +72% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,734 | $0 M | — | <0.01% | +2377% | May 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,057 | $0 M | — | <0.01% | −26% | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,010 | $0 M | — | <0.01% | −30% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Moderate Allocation PortfolioT. Rowe Price Associates, Inc. | 912 | $0 M | — | 0.01% | +3.2% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 869 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,260 | $0 M | — | <0.01% | +73% | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 819 | $0 M | — | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 968 | $0 M | — | 0.01% | new | May 31, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors | 904 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 554 | $0 M | — | 0.01% | +2.0% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 769 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 757 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 488 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 480 | $0 M | — | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 404 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 567 | $0 M | — | <0.01% | +58% | Jul 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 488 | $0 M | — | <0.01% | −92% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 76 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 61 | $0 M | — | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 95 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aktis Oncology, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Akos CzibereChief Medical Officer | Option exercise10b5-1 plan | +12,500 | $4.950 | $62 K | 12,500 | Form 4 |
| filed | Akos CzibereChief Medical Officer | Sell10b5-1 plan | -5,099 | $20.19 | $103 K | 7,401 | Form 4 |
| filed | Akos CzibereChief Medical Officer | Sell10b5-1 plan | -7,401 | $21.03 | $156 K | 0 | Form 4 |
| filed | Ken HerrmannDirector | Option exercise | +3,506 | $0.080 | — | 3,506 | Form 4 |
| filed | Ken HerrmannDirector | Option exercise | +1,350 | $1.910 | $3 K | 4,856 | Form 4 |
| filed | Ken HerrmannDirector | Sell | -3,506 | $24.56 | $86 K | 1,350 | Form 4 |
| filed | Ken HerrmannDirector | Sell | -1,350 | $24.56 | $33 K | 0 | Form 4 |
| filed | Ken HerrmannDirector | Option exercise | +3,065 | $0.080 | — | 3,065 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aktis Oncology, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $18.00, raising $317.7M · IPO calendar
Stock splits: 1-for-3.8 reverse split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aktis Oncology, Inc. scorecard#
Passes 1 of the 1 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.37 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Aktis Oncology, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Bylaws or fiscal year changed 1 · Results announced 4
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2024 | $175 M | No. 1 | $50 to $250 million | 39 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Aktis Oncology, Inc.#
2 labor condition applications certified in fiscal 2024 for 2 positions, at a median wage of $125 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, Lead DiscoveryMolecular and Cellular Biologists | 1 | $94 K |
| Principal Scientist, Oncology ResearchBiochemists and Biophysicists | 1 | $155 K |
Where: Boston, MA 2
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aktis Oncology, Inc.
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aktis Oncology, Inc.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 5, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aktis Oncology, Inc.? Verify and update this profile — free
Show Aktis Oncology, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.